By Patrick Wingrove Sept 7 (Reuters) - Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's ...

Novo Nordisk A/S stopped two more trials for its experimental heart disease medicine, in a further blow to the drug’s prospects. Earlier this year Novo said ziltivekimab failed to reduce the risk of ...

According to a report on September 7, 2026, Novo Nordisk announced that it has halted two additional clinical trials of its experimental cardiovascular drug ziltivekimab due to lack of efficacy, ...

Novo Nordisk (NVO) has halted two late-stage trials of its experimental heart drug ziltivekimab, adding to the drugmaker’s recent pipeline setbacks. The Danish company said on Monday that an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Nearly 1 million HealthCare.gov enrollees who paid full price are getting $500 checks. See who qualifies and how to avoid scams tied to the payments. New CPSC recalls cover Amazon baby bath seats and ...

Add Yahoo as a preferred source to see more of our stories on Google. The HERMES and ATHENA trials will stop due to a data monitoring committee's recommendation. Credit: Below the Sky / ...

Novo Nordisk halts two more ziltivekimab heart-failure trials after a data monitor found limited likelihood of success, leaving only the ARTEMIS post-MI study active. Novo Nordisk's STEP Young trial ...

On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker’s ...